

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Protocol for a Scoping Review to Support Development of a CONSORT Extension for RCTs Using Cohorts and Routinely Collected Health Data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025266
Article Type:	Protocol
Date Submitted by the Author:	06-Jul-2018
Complete List of Authors:	<p>Kwakkenbos, Linda; Radboud Universiteit Faculteit der Sociale Wetenschappen, Behavioural Science Institute  Imran, Mahrukh; Jewish General Hospital, Lady Davis Institute for Medical Research  Mc Cord, Kimberly; Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, University of Basel  Sampson, Margaret; Children's Hospital of Eastern Ontario Research Institute,  Fröbert, O; Örebro University,  Gale, Chris; Section of Neonatal Medicine, Department of Medicine, Imperial College London, Chelsea and Westminster campus  Hemkens, Lars; Basel University Hospital, Basel Institute for Clinical Epidemiology and Biostatistics  Langan, Sinead; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine  Moher, David; Ottawa Hospital Research Institute, Ottawa Methods Centre  Relton, Clare ; Centre for Clinical Trials and Methodology, Barts Institute of Population Health Science, Queen Mary University  Zwarenstein, Merrick; Institute for Clinical Evaluative Sciences  Benchimol, Eric; Department of Pediatrics and School of Epidemiology and Public Health, University of Ottawa  Boutron, Isabelle; Université Paris Descartes, Centre d'épidémiologie clinique  Campbell, Marion; University of Aberdeen, Health Services Research Unit  Erlinge, David; Lunds Universitet, Clinical science  Jawad, Sena; Neonatal Data Analysis Unit, Department of Medicine, Imperial College London  Ravaud, Philippe; Université Paris Descartes, Centre d'épidémiologie clinique; INSERM U1153  Rice, Danielle; Lady Davis Institute, Jewish General Hospital, Psychiatry; McGill University, Psychology  Sauve, Maureen; Scleroderma Societies of Canada and Ontario,  van Staa, Tjeerd; Health e-Research Centre, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester; Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University  Thabane, Lehana ; McMaster University, Clinical Epidemiology &amp; Biostatistics  Uher, Rudolf; Department of Psychiatry, Dalhousie University</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Verkooijen, Helena; University Medical Center Utrecht, Imaging Division Trial office Juszcak, Ed; Oxford Brookes University Faculty of Health and Life Sciences, NPEU Clinical Trials Unit, National Perinatal Epidemiology Unit, Nuffield Department of Population Health Thombs, Brett; McGill University, Psychiatry
Keywords:	cohort, CONSORT, randomized controlled trials, reporting guideline, routinely collected health data, RCTs

SCHOLARONE™  
Manuscripts

For peer review only

1  
2  
3 **Protocol for a Scoping Review to Support Development of a CONSORT Extension**  
4 **for Randomized Controlled Trials Using Cohorts and Routinely Collected Health**  
5 **Data**  
6  
7  
8  
9

10  
11  
12  
13  
14 Linda Kwakkenbos<sup>1</sup>; Mahrukh Imran<sup>2</sup>; Kimberly A. Mc Cord<sup>3</sup>; Margaret Sampson<sup>4</sup>; Ole  
15 Fröbert<sup>5</sup>; Chris Gale<sup>6</sup>; Lars G. Hemkens<sup>3</sup>; Sinéad M. Langan<sup>7</sup>; David Moher<sup>8</sup>; Clare  
16 Relton<sup>9</sup>; Merrick Zwarenstein<sup>10,11</sup>; Eric I. Benchimol<sup>12,13,14</sup>; Isabelle Boutron<sup>15,16,17</sup>;  
17 Marion K. Campbell<sup>18</sup>; David Erlinge<sup>19</sup>; Sena Jawad<sup>6</sup>; Philippe Ravaud<sup>15,16,17</sup>; Danielle  
18 Rice<sup>2,20</sup>; Maureen Sauv <sup>21,22</sup>; Tjeerd P. van Staa<sup>23,24</sup>; Lehana Thabane<sup>25</sup>; Rudolf Uher<sup>26</sup>;  
19 Helena M. Verkooijen<sup>27,28</sup>; Edmund Juszcak<sup>29</sup>; Brett D. Thombs<sup>2,20,30</sup>  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 <sup>1</sup>Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, the  
32 Netherlands; <sup>2</sup>Lady Davis Institute for Medical Research, Jewish General Hospital,  
33 Montreal, Canada; <sup>3</sup>Basel Institute for Clinical Epidemiology and Biostatistics,  
34 Department of Clinical Research, University Hospital Basel, University of Basel, Basel,  
35 Switzerland; <sup>4</sup>Library Services, Children's Hospital of Eastern Ontario, Ottawa, Canada;  
36  
37 <sup>5</sup>Örebro University, Faculty of Health, Department of Cardiology, Örebro, Sweden;  
38  
39 <sup>6</sup>Section of Neonatal Medicine, Department of Medicine, Imperial College London,  
40 Chelsea and Westminster campus, London, UK; <sup>7</sup>Faculty of Epidemiology and  
41 Population Health, London School of Hygiene and Tropical Medicine, London, UK;  
42  
43 <sup>8</sup>Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research  
44 Institute, Ottawa, Canada; <sup>9</sup>Centre for Clinical Trials and Methodology, Barts Institute of  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Population Health Science, Queen Mary University, London, UK; <sup>10</sup>Department of  
4  
5 Family Medicine, Western University, London, Canada; <sup>11</sup>Institute for Clinical  
6  
7 Evaluative Sciences, Toronto, Canada; <sup>12</sup>Department of Pediatrics and School of  
8  
9 Epidemiology and Public Health, University of Ottawa, Ottawa, Canada; <sup>13</sup>Institute for  
10  
11 Clinical Evaluative Sciences, Ottawa, Canada; <sup>14</sup>Division of Gastroenterology,  
12  
13 Hepatology and Nutrition, Children's Hospital of Eastern Ontario, Ottawa, Canada;  
14  
15 <sup>15</sup>INSERM, UMR1153, Paris, France; <sup>16</sup>Centre d'Épidémiologie Clinique, Hôpital Hôtel  
16  
17 Dieu, Assistance Publique–Hôpitaux de Paris, Paris, France; <sup>17</sup>Faculté de Médecine,  
18  
19 Université Paris Descartes, Sorbonne Paris Cité, Paris, France; <sup>18</sup>Health Services  
20  
21 Research Unit, University of Aberdeen, Aberdeen, UK; <sup>19</sup>Department of Cardiology,  
22  
23 Clinical Sciences, Lund University, Lund, Sweden; <sup>20</sup>Department of Psychology, McGill  
24  
25 University, Montréal, Québec, Canada; <sup>21</sup>Scleroderma Society of Ontario, Hamilton,  
26  
27 Canada; <sup>22</sup>Scleroderma Canada, Hamilton, Canada; <sup>23</sup>Health e-Research Centre, School  
28  
29 of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester,  
30  
31 Manchester, UK; <sup>24</sup>Faculty of Science, Division of Pharmacoepidemiology and Clinical  
32  
33 Pharmacology, Utrecht University, Utrecht, the Netherlands; <sup>25</sup>Department of Health  
34  
35 Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada;  
36  
37 <sup>26</sup>Department of Psychiatry, Dalhousie University, Halifax, Canada; <sup>27</sup>University Medical  
38  
39 Center Utrecht, Utrecht, the Netherlands; <sup>28</sup>University of Utrecht, Utrecht, the  
40  
41 Netherlands; <sup>29</sup>NPEU Clinical Trials Unit, National Perinatal Epidemiology Unit,  
42  
43 Nuffield Department of Population Health, University of Oxford, UK; <sup>30</sup>Departments of  
44  
45 Psychiatry; Epidemiology, Biostatistics and Occupational Health; Medicine; and  
46  
47 Educational and Counselling Psychology, McGill University, Montreal, Canada  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 **Address for Correspondence:** Brett D. Thombs, PhD; Jewish General Hospital; 4333  
6  
7 Cote Ste Catherine Road; Montreal, Quebec H3T 1E4; Tel (514) 340-8222 ext. 25112; E-  
8  
9 mail: brett.thombs@mcgill.ca  
10  
11  
12  
13

14  
15 **Author Email Addresses:**

16 kwakkenbosl@gmail.com

17 mahrukh.imran@mail.mcgill.ca

18 kimberlyalba.mccord@usb.ch

19 msampson@cheo.on.ca

20 ole.frobert@regionorebrolan.se

21 christopher.gale@imperial.ac.uk

22 lars.hemkens@usb.ch

23 sinead.langan@lshtm.ac.uk

24 dmoher@ohri.ca

25 c.relton@qmul.ac.uk

26 merrick.zwarenstein@ices.on.ca

27 eric@benchimol.ca

28 isabelle.boutron@aphp.fr

29 m.k.campbell@abdn.ac.uk

30 david.erlinge@gmail.com

31 s.jawad@imperial.ac.uk

32 philippe.ravaud@aphp.fr

1  
2  
3 danielle.rice@mail.mcgill.ca  
4

5 maureen.sauve@gmail.com  
6

7 tjeerd.vanstaa@manchester.ac.uk  
8

9  
10 thabanl@mcmaster.ca  
11

12 uher@dal.ca  
13

14 h.m.verkooijen@umcutrecht.nl  
15

16 ed.juszczak@npeu.ox.ac.uk  
17

18  
19 brett.thombs@mcgill.ca  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Randomized controlled trials (RCTs) conducted using cohorts and routinely collected health data, including registries, electronic health records, and administrative databases, are increasingly used in health care intervention research. The development of an extension of the CONSolidated Standards of Reporting Trials (CONSORT) statement for RCTs using cohorts and routinely collected health data is being undertaken with the goal of improving reporting quality by setting standards early in the process of uptake of these designs. To develop this extension to the CONSORT statement, a scoping review will be conducted to identify potential modifications or clarifications of existing reporting guideline items, as well as additional items needed for reporting RCTs using cohorts and routinely collected health data.

**Methods and analysis:** In separate searches, we will seek publications on methods or reporting or that describe protocols or results from RCTs using cohorts, registries, electronic health records and administrative databases. Data sources will include Medline and the Cochrane Methodology Register. For each of the four main types of RCTs using cohorts and routinely collected health data, separately, two investigators will independently review included publications to extract potential checklist items. A potential item will either modify an existing CONSORT 2010, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) or REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) item or will be proposed as a new item. Additionally, we will identify examples of good reporting in RCTs using cohorts and routinely collected health data.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Ethics and dissemination:** The proposed scoping review will help guide the development of the CONSORT extension statement for RCTs conducted using cohorts and routinely collected health data.

For peer review only

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- Our scoping review will be conducted using rigorous methods, with peer-reviewed searches developed by a research librarian that will comply with Institute of Medicine standards and are not limited by language.
- Due to the novelty of RCTs using cohorts and routinely collected health data, we anticipate identifying only a limited number of methods and reporting articles in our scoping review.
- To supplement articles on methods and reporting, we will review primary trial protocols and reports to identify elements that need reporting and to identify examples of good reporting.

## INTRODUCTION

Randomized controlled trials (RCTs), when well-designed and conducted, are widely acknowledged to be the gold standard for evaluating the effectiveness and harms of medical interventions.<sup>1-3</sup> Important concerns exist, however, about many RCTs, including limitations related to difficulty recruiting sufficiently large and representative samples, limited real-world generalizability, and prohibitive costs.<sup>4-12</sup> To attempt to address these and other challenges, trial designs have been developed in which RCTs are conducted within the frameworks cohorts<sup>4</sup> and routinely collected health data. Routinely collected health data are defined as data collected for administrative and clinical purposes, without specific *a priori* research questions<sup>13</sup>, and include registries<sup>14</sup>, electronic health records<sup>15</sup>, and health administrative databases.<sup>16</sup>

Biomedical research reporting guidelines have been developed to assist authors to report research studies as accurately, transparently, and completely as possible. Reporting guidelines typically describe a minimum set of information that should be clearly reported, provide examples of guideline-consistent reporting, and include a checklist to facilitate compliance.<sup>17,18</sup> Multiple existing reporting guidelines include items that are potentially applicable to RCTs conducted using cohorts and routinely collected health data. In addition to the Consolidated Standards of Reporting Trials (CONSORT) statement for reporting of parallel group RCTs,<sup>19</sup> reporting guidelines with the most direct overlap include the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline for the reporting of observational studies, generally,<sup>20</sup> and the REporting of studies Conducted using Observational Routinely

1  
2  
3 collected Data (RECORD) guideline,<sup>21</sup> which addresses reporting specific to  
4  
5 observational studies conducted using routinely collected health data.  
6

7  
8 The development of an extension of the CONSORT statement for RCTs conducted  
9  
10 using cohorts and routinely collected health data is being undertaken with the goal of  
11  
12 improving long-term reporting quality by setting standards early in the process of uptake  
13  
14 of these trial designs.<sup>22</sup> To develop this CONSORT extension, information is needed to  
15  
16 understand which items from CONSORT, STROBE, and RECORD can be utilized  
17  
18 without modification and which should be included with adaptations, as well as aspects  
19  
20 of reporting of RCTs conducted using cohorts and routinely collected health data that are  
21  
22 not covered adequately in these reporting guidelines and that require new reporting items.  
23  
24 In addition, examples of complete and transparent reporting of different aspects of these  
25  
26 RCTs are needed.  
27  
28  
29

30  
31 Relatively little guidance has been published on the methods and reporting of RCTs  
32  
33 conducted using cohorts and routinely collected health data. To account for this, the  
34  
35 proposed scoping review will identify articles on the methods or reporting of RCTs  
36  
37 conducted using cohorts, registries, electronic health records, and health administrative  
38  
39 databases, as well as examples of protocols and reports of results from these types of  
40  
41 RCTs. The objectives of the scoping review are to (1) determine which items from an  
42  
43 initial long list of items based on CONSORT, STROBE, and RECORD that are being  
44  
45 considered for possible inclusion in the CONSORT extension can be included without  
46  
47 modification, identify items from the initial list that need adaptation, and identify  
48  
49 additional reporting considerations to develop new items; and (2) identify examples of  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 complete and transparent reporting of different aspects of these types of RCTs that can be  
4  
5 used to support the CONSORT extension.  
6

## 7 8 **METHODS**

9  
10 The scoping review will be conducted following the approach described by Arksey  
11 and O'Malley<sup>23</sup> and will be reported using the Preferred Reporting Items for Systematic  
12 Reviews and Meta-Analysis: extension for Scoping Reviews (PRISMA-ScR)  
13  
14  
15  
16  
17 guidelines.<sup>24</sup>

### 18 19 *Database Searches*

20  
21 In separate searches, we will seek publications that describe aspects of methods or  
22 reporting or that describe protocols or results from RCTs (including cluster RCTs) using  
23  
24 (1) cohorts; (2) registries; (3) electronic health records; and (4) health administrative  
25  
26  
27  
28 databases. Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed  
29 Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE and EBM Reviews - Cochrane  
30  
31  
32 Methodology Registry (Final issue, 3rd Quarter 2012) will be searched by an experienced  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
librarian familiar with knowledge synthesis for publications on methods or reporting of  
these types of RCTs and for examples of these types of RCTs. MEDLINE strategies for  
the searches were developed by a research librarian with input from the project team and  
were peer reviewed using the Peer Review of the Electronic Search Strategy (PRESS)  
standard.<sup>25</sup> The MEDLINE strategy was then adapted for the Cochrane Library  
Methodology Register, which includes methodological research available up to its last  
update in July 2012.

51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Search strategies comply with Institute of Medicine standards and are not limited  
by language.<sup>26</sup> We will search for articles on methods and reporting and examples of

1  
2  
3 RCTs published in the last 10 years (2008-2018), which will allow us to identify  
4 relatively recent reporting practices and focus on challenging aspects of reporting. See  
5 Supplementary File 1 for detailed search strategies. In addition to the database searches,  
6 references of included studies will be reviewed for additional eligible studies, a web  
7 search will be conducted, and members of the project team with experience in each type  
8 of trial will be consulted to provide additional studies that were not identified in our  
9 search.

### 19 ***Study Selection***

21 For each search, separately, results will be downloaded into the citation  
22 management database RefWorks, and duplicate references will be removed. Following  
23 this, references will be transferred into the systematic review software DistillerSR<sup>®</sup>  
24 (Evidence Partners, Ottawa, Canada). A coding manual based on eligibility criteria has  
25 been developed, and a pilot test of the coding manual will be performed prior to the  
26 study's inception. The initial coding manuals for inclusion and exclusion for all four  
27 types of trial designs are shown in Supplementary File 2. Because the trial designs that  
28 will be included in the CONSORT extension reflect relatively recent developments, we  
29 anticipate that we will identify only a small number of articles on their methodology and  
30 reporting. Thus, we will also include publications of trial protocols and results.

31 We will assess the eligibility of each publication through a two-stage process. In  
32 the first stage, two reviewers will independently screen titles and abstracts to identify  
33 potentially relevant studies. We will use a liberal accelerated method<sup>27</sup> to screen titles and  
34 abstracts, meaning that articles deemed eligible by one of the reviewers will be included  
35 in full-text review, and only excluded articles will be screened by a second reviewer.

1  
2  
3 Since title and abstract screening is done randomly and concurrently, reviewers will not  
4 know if the other reviewer has excluded the reference or not. In the second stage, two  
5 investigators will independently conduct a full-text review. Disagreements after full-text  
6 review will be resolved by consensus, with a third investigator consulted as necessary.  
7  
8 Translators will be consulted to evaluate titles and abstracts and full-text articles for  
9 languages other than those for which team members are fluent, if any. See Supplementary  
10 File 3 for the preliminary PRISMA flow of studies figures for the four types of trial  
11 designs.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 ***Data Extraction and Verification***

23  
24 To develop a preliminary 'long list' of items to consider for the CONSORT  
25 extension checklist, as an initial step, items from the CONSORT 2010 will be examined  
26 to identify items where modifications will be needed for RCTs conducted using cohorts  
27 and routinely collected health data, and items from the STROBE and RECORD reporting  
28 guidelines will be examined to identify additional items to complement CONSORT  
29 items. Two investigators will independently review these reporting guidelines, and any  
30 item deemed possibly relevant to RCTs using cohorts and routinely collected health data  
31 by either or both investigator, will be included in the 'long list'. Additional preliminary  
32 'long list' items will be provided by other members of the project team.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 For each of the four types of RCTs conducted using cohorts and routinely  
45 collected health data, separately, two investigators will independently review included  
46 publications to extract additional potential items for the 'long list'. A potential item will  
47 either modify an existing CONSORT 2010, STROBE or RECORD item that has been  
48 included in the 'long list' or will be proposed as a new item. Potential items will be  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 identified from publications that report information relevant to conducting RCTs using  
4 cohorts and routinely collected health data, but that were not included in our initial ‘long  
5 list’. In addition, potential items will be suggested based on gaps in reporting identified  
6 from primary trial protocols or reports. Data will be extracted and collected in  
7 DistillerSR<sup>®</sup> using a standardized data extraction form. The long-list of items will evolve  
8 dynamically as potential modifications and new items are added based on the review of  
9 publications identified from our literature search using the DistillerSR<sup>®</sup> Dynamic  
10 Question function. Thus, reviewers will add a potential item only once to the long-list,  
11 after which it becomes visible for all reviewers. Reviewers will not duplicate items  
12 already provided by other reviewers. This will be done to avoid redundancy, as we expect  
13 potential gaps in reporting to occur in multiple publications that will be reviewed. In  
14 addition to each proposed item modification or new item, reviewers will add a brief  
15 explanation of why the suggested modification or new item is deemed important.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 In addition to identifying gaps in reporting, for each item on our long list, we will  
34 attempt to identify examples of complete and transparent reporting in RCTs using  
35 cohorts, registries, electronic health record, and health administrative databases. When  
36 examples of complete and transparent reporting for a particular item on the long list are  
37 identified, text corresponding to reporting of that item will be inserted in the data  
38 extraction form in DistillerSR<sup>®</sup>.  
39  
40  
41  
42  
43  
44  
45  
46

47 Prior to data extraction from included studies, all reviewers will assess a sample  
48 of trial reports. The results will be compared and discussed among the reviewers in order  
49 to ensure consistent application of the data extraction process.  
50  
51  
52

## 53 **CONCLUSION**

54  
55  
56  
57  
58  
59  
60



1  
2  
3 This scoping review will gather previously published methods and  
4  
5 recommendations for the reporting of RCTs using cohorts and routinely collected health  
6  
7 data, as well as identify gaps in reporting of these studies. We will identify potential  
8  
9 modifications or clarifications of CONSORT 2010, STROBE and RECORD items as  
10  
11 well as potential additional items to develop an extension to the CONSORT statement for  
12  
13 reporting RCTs using cohorts and routinely collected health data. Following the scoping  
14  
15 review, identified items will be vetted using a 3-stage Delphi approach<sup>28</sup> and a face-to-  
16  
17 face meeting, after which the reporting checklist and explanation and elaboration  
18  
19 documents for the CONSORT extension will be finalized. The resulting CONSORT  
20  
21 extension will promote transparency, clarity, reduce research waste and provide guidance  
22  
23 to researchers on appropriate and consistent reporting of RCTs using cohorts and  
24  
25 routinely collected health data.  
26  
27  
28  
29

### 30 **ETHICS AND DISSEMINATION**

31  
32 This study does not require ethics approval, as required data will be collected through the  
33  
34 review of published literature. The proposed scoping review will help guide the  
35  
36 development of the CONSORT extension statement for RCTs conducted using cohorts  
37  
38 and routinely collected health data. The findings will be disseminated through peer-  
39  
40 reviewed publications and conference presentations.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **AUTHORS' CONTRIBUTIONS**

LK, MI, EJ, LGH, OF, CR, CG, MZ, SML, DM, and BDT held regular meetings to develop the conceptual framework, and project process and all other team members provided feedback. LK, MI and BDT were responsible for the first draft of the manuscript. All authors made contributions to previous drafts of the manuscript and approved the final version.

## **FUNDING STATEMENT**

The development of this CONSORT extension has been funded by grants from the Canadian Institutes of Health Research (PIs = BDT, OF, EJ, LK, CR; Grant #PJT-156172), and from the United Kingdom National Institute of Health Research (NIHR) Clinical Trials Unit Support Funding - Supporting efficient / innovative delivery of NIHR research (PI EJ, co-applicant CG). Dr. Thombs is supported by a Fonds de recherche du Québec - Santé researcher salary award. Dr. Gale is supported by the United Kingdom Medical Research Council through a Clinician Scientist Fellowship. Dr. Langan is supported by a Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z). Dr. Uher is supported by the Canada Research Chairs Program (Award #231397). Dr. Benchimol is supported by a New Investigator Award from the Canadian Institutes of Health Research, Canadian Association of Gastroenterology and Crohn's and Colitis Canada, and the Career Enhancement Program of the Canadian Child Health Clinician Scientist Program. Ms. Rice is supported by a Vanier CIHR Graduate Scholarship. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

1  
2  
3  
4  
5 **COMPETING INTERESTS STATEMENT**  
6

7  
8 The authors have read and understood the BMJ policy on declaration of interests and  
9  
10 declare that they have no competing interests.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Torgerson D, Torgerson C. Designing randomised trials. Basingstoke: Palgrave; 2008.
2. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. *J Chron Dis* 1967;20:637–48.
3. Evans I, Thornton H, Chalmers I, Glasziou P. Testing Treatments: Better research for better healthcare. London: Pinter and Martin Ltd; 2011.
4. Relton C, Torgerson D, O’Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. *BMJ* 2010;340:2.
5. Treweek S, Mitchell E, Pitkethly M, Cook J, Kjeldstrøm M, Taskila T, et al. Strategies to improve recruitment to randomised controlled trials. *Cochrane Database Syst Rev* 2010;4:MRMR000013.
6. Watson J, Torgerson D. Increasing recruitment to randomised trials: a review of randomised controlled trials. *BMC Med Res Methodol* 2006;6:34.
7. Campbell M, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, et al. Recruitment to randomised trials: strategies for trial enrolment and participation study: the STEPS study. *Health Technol Assess* 2007;11:48 iii, ix-105.
8. Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrøm M, Johansen M, et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. *BMJ Open* 2013;3:e002360.

- 1  
2  
3 9. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised,  
4 controlled, multicenter trials: a review of trials funded by two UK funding  
5 agencies. *Trials* 2013;14:166.  
6  
7
- 8  
9  
10 10. McDonald AM, Treweek S, Shakur H, Free C, Knight R, Speed C, et al. Using a  
11 business model approach and marketing techniques for recruitment to clinical trials.  
12 *Trials* 2011;12:74.  
13  
14
- 15 11. Donovan JL, Paramasivan S, De Salis I, Toerien M. Clear obstacles and hidden  
16 challenges: understanding recruiter perspectives in six pragmatic randomised  
17 controlled trials. *Trials* 2014;15:5.  
18  
19
- 20 12. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munis BH, Lindborg SR, et  
21 al. How to improve R&D productivity: the pharmaceutical industry's grand  
22 challenge. *Nat Rev Drug Discov* 2010;9:203-14.  
23  
24
- 25 13. Spasoff RA. *Epidemiologic Methods for Health Policy*. New York: Oxford  
26 University Press, Inc.; 1999.  
27  
28
- 29 14. James S, Fröbert O, Lagerqvist B. Cardiovascular registries: a novel platform for  
30 randomised clinical trials. *Heart* 2012;98:1329-31.  
31  
32
- 33 15. van Staa TP, Dyson L, McCann G, Padmanabhan S, Belatri R, Goldacre B, et al.  
34 The opportunities and challenges of pragmatic point-of-care randomised trials using  
35 routinely collected electronic records: evaluations of two exemplar trials. *Health*  
36 *Technol Assess* 2014;18:1-146.  
37  
38
- 39 16. Anderson GL, Burns CJ, Larsen J, Shaw PA. Use of administrative data to increase  
40 the practicality of clinical trials: Insights from the Women's Health Initiative. *Clin*  
41 *Trials* 2016;13:519-26  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

17. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. *Lancet* 2014;383:267-76.
18. Simera, I., Moher, D., Hoey, J., Schulz, K. F., & Altman, D. G. (2010). A catalogue of reporting guidelines for health research. *European journal of clinical investigation*, 40(1), 35-53.
19. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 23;340:c332.
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370:1453-7.
21. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Med.* 2015;12:e1001885.
22. Kwakkenbos L, Juszczak E, Hemkens LG, Sampson M, Fröbert O, Relton C, et al. Protocol for the Development of a CONSORT Extension for Trials Using Cohorts and Routinely Collected Health Data. *Res Integr Peer Rev.* Submitted.
23. Arksey H, O'Malley L. Scoping studies: Towards a Methodological Framework. *International journal of social research methodology.* 2005;8:19-32.
24. Tricco A, Straus S, Moher D. Preferred reporting items for systematic reviews and meta-analysis: extension for Scoping Reviews (PRISMA-ScR). EQUATOR Netw

- 1  
2  
3 [http://www.equator-network.org/wp-content/uploads/2009/02/Executive-](http://www.equator-network.org/wp-content/uploads/2009/02/Executive-summary_ScR_Dec-9.pdf)  
4 [summary\\_ScR\\_Dec-9.pdf](http://www.equator-network.org/wp-content/uploads/2009/02/Executive-summary_ScR_Dec-9.pdf) (accessed 20 May 2017). 2017.  
5  
6  
7  
8 25. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS  
9 peer review of electronic search strategies: 2015 guideline statement. *J Clin*  
10 *Epidemiology* 2016;75:40-6.  
11  
12  
13  
14 26. Institute of Medicine. (2011). Finding What Works in Health Care: Standards for  
15 Systematic Reviews. Standard 3.1 Conduct a comprehensive systematic search for  
16 evidence. Washington DC: Institute of Medicine. Available  
17 at [http://iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-](http://iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews/Standards.aspx)  
18 [Systematic-Reviews/Standards.aspx](http://iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews/Standards.aspx). Accessed 13 March 2018.  
19  
20  
21  
22  
23  
24  
25  
26 27. Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence summaries:  
27 the evolution of a rapid review approach. *Syst Rev* 2012;1:10.  
28  
29  
30  
31 28. Trevelyan E, Robinson N. Delphi methodology in health research: how to do it?  
32 *Eur J of Int Med* 2015;7:423-428.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Supplementary File 1 – Electronic Search Strategies

Searches were run in both MEDLINE and Cochrane Methodology Register simultaneously. As an example, in the registries search, lines 1-11 are the MEDLINE search and lines 12-15 are tailored for the Cochrane Methodology Register. The final lines of each search isolate the records from each database, combine them so duplicate records can be removed, then isolate the remaining records so they can be downloaded and imported into Reference Manager using customized import filters.

### Searches for RCTs embedded in Registries

1. ((registry or registries) adj5 randomi#ed).ab,kf,ti.
2. ((registry or registries) adj5 RCT\*).ab,kf,ti.)
3. ((registry or registries) adj5 controlled trial\*).ab,kf,ti.
4. ((registry or registries) adj5 (RRCT\* or R RCT\*)).ab,kf,ti.
5. or/1-4
6. (meta analy\* or metaanaly\* or metanaly\* or systematic review\*).af.
7. 5 not 6
8. Registries/
9. limit 8 to randomized controlled trial
10. 7 or 9
11. limit 10 to yr="2007 - 2018"
12. (registry or registries).ab,kf,ti.
13. (random\* or RCT).ti,ab,kw.
14. 12 and 13
15. limit 14 to yr="2007 - 2018"
16. 11 use medall
17. 15 use clcmr
18. 16 or 17 (1240)
19. remove duplicates from 18
20. 19 use medall
21. 19 use clcmr

### Searches for RCTs embedded in Cohorts

1. (cohort adj5 (randomi#ed adj5 trial\*)).ab,kf,ti.
2. (cohort adj5 RCT\*).ab,kf,ti.
3. (cohort adj5 controlled trial\*).ab,kf,ti.
4. (cmRCT or Cohort Multiple Randomised Controlled Trial\*).ab,kf,ti.
5. or/1-4
6. cohort.af.
7. (embed\* adj8 randomi#ed).ab,kf,ti.
8. (embed\* adj8 RCT\*).ab,kf,ti.
9. (embed\* adj8 controlled trial\*).ab,kf,ti.
10. or/7-9
11. 6 and 10
12. (pragmatic adj5 RCT\*).ab,kf,ti.
13. (pragmatic adj5 randomi#ed).ab,kf,ti.



14. (pragmatic adj5 controlled trial\*).ab,kf,ti.
15. or/12-14
16. 6 and 15
17. 5 or 11 or 16
18. (meta analy\* or metaanaly\* or metanaly\* or systematic review\*).af.
19. 17 not 18
20. limit 19 to yr="2007 - 2018"
21. ((Cohort\* and (random\* or RCT)) or cmRCT).ti,ab,kw.
22. limit 21 to yr="2007 - 2018"
23. 20 use medall
24. 22 use clcmr
25. 23 or 24
26. remove duplicates from 25
27. 26 use medall
28. 26 use clcmr

### Searches for RCTs embedded in Electronic Health Records

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomi?ed.ab.
4. placebo.ab.
5. randomly.ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Electronic Health Records/
12. (EHR or electronic health record\*).ab,kf,ti.
13. (EMR or electronic medical record\*).ab,kf,ti.
14. (PHR or personal health record\*).ab,kf,ti.
15. (EPR or electronic patient record\*).ab,kf,ti.
16. exp Health Records, Personal/
17. or/11-16
18. 10 and 17
19. limit 18 to yr="2007 - 2018"
20. (Electronic health record or electronic health records or EHR).ti,ab,kw.
21. (Electronic medical record or electronic medical records or EMR).ti,ab,kw.
22. (Electronic patient record or electronic patient records or EPR).ti,ab,kw.
23. or/20-22
24. limit 23 to yr="2007 - 2018"
25. 19 use medall
26. 24 use clcmr
27. 25 or 26
28. remove duplicates from 27
29. 28 use medall
30. 28 use clcmr

### Searches for RCTs embedded in Administrative Databases

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomi?ed.ab.
4. placebo.ab.
5. randomly.ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. administrative data\*.ab,kf,ti.
12. healthcare data\*.ab,kf,ti.
13. health care data\*.ab,kf,ti.
14. or/11-13
15. 10 and 14
16. (administrative adj5 data\*).ti,ab,kw.
17. health care data\*.ti,ab,kw.
18. healthcare data\*.ti,ab,kw.
19. or/16-18
20. (random\* or RCT).ti,ab,kw.
21. 19 and 20
22. limit 15 to yr="2007 - 2018"
23. 22 use medall
24. limit 21 to yr="2007 - 2018"
25. 22 use clcmr

## Supplementary File 2 – Coding Manual

### Title/Abstract Screening

#### **Does this study meet the title and abstract inclusion criteria for Cohort-based Randomized Controlled Trials (RCTs)?**

**No: not an RCT using a cohort.** If it is clear from the title and abstract that the publication does not describe (1) issues related to methods or reporting of cohort-based RCTs, (2) a cohort intended to be used to conduct RCTs, or (3) a protocol or results from a RCT that will select or selected individuals from a cohort, it is excluded. For the purpose of this review, a cohort is defined as a group of individuals who are gathered for the purpose of conducting research and for whom there are multiple assessments over time. If it is clear from the title and abstract that the publication describes a study that enrolls patients only in a cohort or only in an RCT (e.g., comparative cohort trials, parallel cohorts) – but not both, it is excluded. If (observational) analyses are done on all participants or a subgroup of participants who were enrolled in an RCT, even if described by the authors as a 'cohort', it would be excluded. If the RCT involves non-human subjects, it is excluded.

**No: the cohort is only used for identifying eligible participants.** If it is clear from the title and abstract that the publication describes a trial in which a cohort was solely used to identify eligible trial participants, but for no other purposes related to the trial, it is excluded.

**No: the cohort is only used for collecting trial outcomes.** If it is clear from the title and abstract that the publication describes a trial that only links to a cohort to ascertain health outcomes as trial endpoints, but does not otherwise use the cohort in the trial, it is excluded.

**Yes: study eligible to be included in full-text review.**

1  
2  
3 **Does this study meet the title and abstract inclusion criteria for Registry-based**  
4 **Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using a registry.** If it is clear from the title and abstract that the  
8 publication does not describe (1) issues related to methods or reporting of registry-based  
9 RCTs, (2) a registry used to conduct RCTs, or (3) a protocol or results from a RCT  
10 conducted using a registry, it is excluded. A registry has been defined by the European  
11 Medicines Agency as “an organized system that uses observational methods to collect  
12 uniform data on specified outcomes in a population defined by a particular disease,  
13 condition, or exposure, and that is followed over time.” Entry in a registry is generally  
14 defined either by diagnosis of a disease (disease registry) or prescription of a drug,  
15 device, or other treatment (exposure registry). If the RCT involves non-human subjects, it  
16 is excluded.  
17  
18

19 **No: the registry is only used for identifying eligible participants.** If it is clear from the  
20 title and abstract that the publication describes a trial in which the registry was solely  
21 used to identify eligible trial participants, but for no other purposes related to the trial, it  
22 is excluded.  
23  
24

25 **No: the registry is only used for collecting trial outcomes.** If it is clear from the title  
26 and abstract that the publication describes a trial that only links to a registry to ascertain  
27 health outcomes as trial endpoints, but does not otherwise use the registry in the trial, it is  
28 excluded.  
29  
30

31 **Yes: study eligible to be included in full-text review.**  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Does this study meet the title and abstract inclusion criteria for Administrative**  
4 **Database-based Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using administrative data.** If it is clear from the title and abstract that  
8 the publication does not describe (1) issues related to methods or reporting of  
9 administrative database-based RCTs, (2) an administrative dataset used to conduct RCTs,  
10 or (3) a protocol or results from a RCT conducted using an administrative database, it is  
11 excluded. Administrative data refers to information collected primarily for administrative  
12 purposes (e.g., all users of healthcare in a province, all persons enrolled in a health  
13 insurance plan). If the RCT involves non-human subjects, it is excluded.  
14

15  
16 **No: the administrative database is only used for identifying eligible participants.** If it  
17 is clear from the title and abstract that the publication describes a trial in which the  
18 administrative database was solely used to identify eligible trial participants, but for no  
19 other purposes related to the trial, it is excluded.  
20

21  
22 **No: the administrative database is only used for collecting trial outcomes.** If it is  
23 clear from the title and abstract that the publication describes a trial that only links to an  
24 administrative database to ascertain health outcomes, as trial endpoints, but does not  
25 otherwise use the administrative database in the trial, it is excluded.  
26

27 **Yes: study eligible to be included in full-text review.**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Does this study meet the title and abstract inclusion criteria for Electronic Health**  
4 **Record (EHR)-based Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using EHRs.** If it is clear from the title and abstract that the publication  
8 does not describe (1) issues related to methods or reporting of electronic health records  
9 (EHR)-based RCTs, (2) EHRs that will be used to conduct RCTs, or (3) a protocol or  
10 results from a RCT conducted using EHRs, it is excluded. EHRs are electronic versions  
11 of a patient's medical history, and can include information that includes diagnoses,  
12 medications, and treatment plans, for instance. If the RCT involves non-human subjects,  
13 it is excluded.  
14

15  
16 **No: the EHR is only used for identifying eligible participants.** If it is clear from the  
17 title and abstract that the publication describes a trial in which the EHR was solely used  
18 to identify eligible trial participants, but for no other purposes related to the trial, it is  
19 excluded.  
20

21  
22 **No: the EHRs is only used to ascertain health outcomes.** If it is clear from the title and  
23 abstract that the publication describes a trial that only links to EHRs to ascertain health  
24 outcomes, as trial endpoints, but does not otherwise use EHRs in the trial, it will be  
25 excluded.  
26

27 **Yes: study eligible to be included in full-text review.**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Full-text review

### **Does this study meet the inclusion criteria for Cohort-based Randomized Controlled Trials (RCTs)?**

**No: not an RCT using a cohort.** If the publication does not describe (1) issues related to methods or reporting of cohort-based RCTs, (2) a cohort intended to be used to conduct RCTs, or (3) a protocol or results from a RCT that will select or selected individuals from a cohort, it is excluded. For the purpose of this review, a cohort is defined as a group of individuals who are gathered for the purpose of conducting research and for whom there are multiple assessments over time. If it is clear from the title and abstract that the publication describes a study that enrolls patients only in a cohort or only in an RCT (e.g., comparative cohort trials, parallel cohorts) – but not both, it is excluded. If (observational) analyses are done on all participants or a subgroup of participants who were enrolled in an RCT, even if described by the authors as a 'cohort', it would be excluded. If the RCT involves non-human subjects, it is excluded.

**No: the cohort is only used for identifying eligible participants.** If the publication describes a trial in which a cohort was solely used to identify eligible trial participants, but for no other purposes related to the trial, it is excluded.

**No: the cohort is only used for collecting trial outcomes.** If the publication describes a trial that only links to a cohort to ascertain health outcomes as trial endpoints, but does not otherwise use the cohort in the trial, it is excluded.

**Yes: study eligible to be included in scoping review.**

1  
2  
3 **Does this study meet the inclusion criteria for Registry-based Randomized**  
4 **Controlled Trials (RCTs)**  
5

6 **No: not an RCT using a registry.** If the publication does not describe (1) issues related  
7 to methods or reporting of registry-based RCTs, (2) a registry used to conduct RCTs, or  
8 (3) a protocol or results from a RCT conducted using a registry, it is excluded. A registry  
9 has been defined by the European Medicines Agency as “an organized system that uses  
10 observational methods to collect uniform data on specified outcomes in a population  
11 defined by a particular disease, condition, or exposure, and that is followed over time.”  
12 Entry in a registry is generally defined either by diagnosis of a disease (disease registry)  
13 or prescription of a drug, device, or other treatment (exposure registry). If the RCT  
14 involves non-human subjects, it is excluded.  
15  
16

17  
18 **No: the registry is only used for identifying eligible participants.** If the publication  
19 describes a trial in which the registry was solely used to identify eligible trial participants,  
20 but for no other purposes related to the trial, it is excluded.  
21

22  
23 **No: the registry is only used for collecting trial outcomes.** If the publication describes  
24 a trial that only links to a registry to ascertain health outcomes as trial endpoints, but does  
25 not otherwise use the registry in the trial, it is excluded.  
26

27 **Yes: study eligible to be included in scoping review.**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **Does this study meet the inclusion criteria for Administrative Database-based**  
4 **Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using administrative data.** If it the publication does not describe (1)  
8 issues related to methods or reporting of administrative database-based RCTs, (2) an  
9 administrative dataset used to conduct RCTs, or (3) a protocol or results from a RCT  
10 conducted using an administrative database, it is excluded. Administrative data refers to  
11 information collected primarily for administrative purposes (e.g., all users of healthcare  
12 in a province, all persons enrolled in a health insurance plan). If the RCT involves non-  
13 human subjects, it is excluded.  
14

15  
16 **No: the administrative database is only used for identifying eligible participants.** If  
17 the publication describes a trial in which the administrative database was solely used to  
18 identify eligible trial participants, but for no other purposes related to the trial, it is  
19 excluded.  
20

21  
22 **No: the administrative database is only used for collecting trial outcomes.** If the  
23 publication describes a trial that only links to an administrative database to ascertain  
24 health outcomes, as trial endpoints, but does not otherwise use the administrative  
25 database in the trial, it is excluded.  
26

27 **Yes: study eligible to be included in scoping review.**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Does this study meet the inclusion criteria for Electronic Health Record (EHR)-**  
4 **based Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using EHRs.** If the publication does not describe (1) issues related to  
8 methods or reporting of electronic health records (EHR)-based RCTs, (2) EHRs that will  
9 be used to conduct RCTs, or (3) a protocol or results from a RCT conducted using EHRs,  
10 it is excluded. EHRs are electronic versions of a patient's medical history, and can  
11 include information that includes diagnoses, medications, and treatment plans, for  
12 instance. If the RCT involves non-human subjects, it is excluded.  
13


14  
15 **No: the EHR is only used for identifying eligible participants.** If the publication  
16 describes a trial in which the EHR was solely used to identify eligible trial participants,  
17 but for no other purposes related to the trial, it is excluded.  
18

19  
20 **No: the EHRs is only used to ascertain health outcomes.** If the publication describes a  
21 trial that only links to EHRs to ascertain health outcomes, as trial endpoints, but does not  
22 otherwise use EHRs in the trial, it will be excluded.  
23


24 **Yes: study eligible to be included in scoping review.**  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Supplementary File 3


## Draft Flow Diagram of Study Selection Process - Cohorts




## Draft Flow Diagram of Study Selection Process - Registries



### Draft Flow Diagram of Study Selection Process – Administrative data



## Draft Flow Diagram of Study Selection Process – Electronic Health Records (EHRs)



# BMJ Open

## Protocol for a Scoping Review to Support Development of a CONSORT Extension for Randomized Controlled Trials Using Cohorts and Routinely Collected Health Data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025266.R1
Article Type:	Protocol
Date Submitted by the Author:	11-Jul-2018
Complete List of Authors:	<p>Kwakkenbos, Linda; Radboud Universiteit Faculteit der Sociale Wetenschappen, Behavioural Science Institute</p> <p>Imran, Mahrukh; Jewish General Hospital, Lady Davis Institute for Medical Research</p> <p>Mc Cord, Kimberly; Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, University of Basel</p> <p>Sampson, Margaret; Children's Hospital of Eastern Ontario Research Institute,</p> <p>Fröbert, O; Örebro University,</p> <p>Gale, Chris; Section of Neonatal Medicine, Department of Medicine, Imperial College London, Chelsea and Westminster campus</p> <p>Hemkens, Lars; Basel University Hospital, Basel Institute for Clinical Epidemiology and Biostatistics</p> <p>Langan, Sinead; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</p> <p>Moher, David; Ottawa Hospital Research Institute, Ottawa Methods Centre</p> <p>Relton, Clare ; Centre for Clinical Trials and Methodology, Barts Institute of Population Health Science, Queen Mary University</p> <p>Zwarenstein, Merrick; Institute for Clinical Evaluative Sciences</p> <p>Benchimol, Eric; Department of Pediatrics and School of Epidemiology and Public Health, University of Ottawa</p> <p>Boutron, Isabelle; Université Paris Descartes, Centre d'épidémiologie clinique</p> <p>Campbell, Marion; University of Aberdeen, Health Services Research Unit</p> <p>Erlinge, David; Lunds Universitet, Clinical science</p> <p>Jawad, Sena; Neonatal Data Analysis Unit, Department of Medicine, Imperial College London</p> <p>Ravaud, Philippe; Université Paris Descartes, Centre d'épidémiologie clinique; INSERM U1153</p> <p>Rice, Danielle; Lady Davis Institute, Jewish General Hospital, Psychiatry; McGill University, Psychology</p> <p>Sauve, Maureen; Scleroderma Societies of Canada and Ontario,</p> <p>van Staa, Tjeerd; Health e-Research Centre, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester; Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University</p> <p>Thabane, Lehana ; McMaster University, Clinical Epidemiology &amp; Biostatistics</p> <p>Uher, Rudolf; Department of Psychiatry, Dalhousie University</p>

	Verkooijen, Helena; University Medical Center Utrecht, Imaging Division Trial office Juszczak, Ed; Oxford Brookes University Faculty of Health and Life Sciences, NPEU Clinical Trials Unit, National Perinatal Epidemiology Unit, Nuffield Department of Population Health Thombs, Brett; McGill University, Psychiatry
<b>Primary Subject Heading</b> :	Research methods
<b>Secondary Subject Heading:</b>	Epidemiology
<b>Keywords:</b>	cohort, CONSORT, randomized controlled trials, reporting guideline, routinely collected health data, RCTs

SCHOLARONE™  
Manuscripts



1  
2  
3 **Protocol for a Scoping Review to Support Development of a CONSORT Extension**  
4 **for Randomized Controlled Trials Using Cohorts and Routinely Collected Health**  
5 **Data**  
6  
7  
8  
9

10  
11  
12  
13  
14 Linda Kwakkenbos<sup>1</sup>; Mahrukh Imran<sup>2</sup>; Kimberly A. Mc Cord<sup>3</sup>; Margaret Sampson<sup>4</sup>; Ole  
15 Fröbert<sup>5</sup>; Chris Gale<sup>6</sup>; Lars G. Hemkens<sup>3</sup>; Sinéad M. Langan<sup>7</sup>; David Moher<sup>8</sup>; Clare  
16 Relton<sup>9</sup>; Merrick Zwarenstein<sup>10,11</sup>; Eric I. Benchimol<sup>12,13,14</sup>; Isabelle Boutron<sup>15,16,17</sup>;  
17 Marion K. Campbell<sup>18</sup>; David Erlinge<sup>19</sup>; Sena Jawad<sup>6</sup>; Philippe Ravaud<sup>15,16,17</sup>; Danielle  
18 Rice<sup>2,20</sup>; Maureen Sauv <sup>21,22</sup>; Tjeerd P. van Staa<sup>23,24</sup>; Lehana Thabane<sup>25</sup>; Rudolf Uher<sup>26</sup>;  
19 Helena M. Verkooijen<sup>27,28</sup>; Edmund Juszcak<sup>29</sup>; Brett D. Thombs<sup>2,20,30</sup>  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 <sup>1</sup>Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, the  
32 Netherlands; <sup>2</sup>Lady Davis Institute for Medical Research, Jewish General Hospital,  
33 Montreal, Canada; <sup>3</sup>Basel Institute for Clinical Epidemiology and Biostatistics,  
34 Department of Clinical Research, University Hospital Basel, University of Basel, Basel,  
35 Switzerland; <sup>4</sup>Library Services, Children's Hospital of Eastern Ontario, Ottawa, Canada;  
36  
37 <sup>5</sup>Örebro University, Faculty of Health, Department of Cardiology, Örebro, Sweden;  
38  
39 <sup>6</sup>Section of Neonatal Medicine, Department of Medicine, Imperial College London,  
40 Chelsea and Westminster campus, London, UK; <sup>7</sup>Faculty of Epidemiology and  
41 Population Health, London School of Hygiene and Tropical Medicine, London, UK;  
42  
43 <sup>8</sup>Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research  
44 Institute, Ottawa, Canada; <sup>9</sup>Centre for Clinical Trials and Methodology, Barts Institute of  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Population Health Science, Queen Mary University, London, UK; <sup>10</sup>Department of  
4  
5 Family Medicine, Western University, London, Canada; <sup>11</sup>Institute for Clinical  
6  
7 Evaluative Sciences, Toronto, Canada; <sup>12</sup>Department of Pediatrics and School of  
8  
9 Epidemiology and Public Health, University of Ottawa, Ottawa, Canada; <sup>13</sup>Institute for  
10  
11 Clinical Evaluative Sciences, Ottawa, Canada; <sup>14</sup>Division of Gastroenterology,  
12  
13 Hepatology and Nutrition, Children's Hospital of Eastern Ontario, Ottawa, Canada;  
14  
15 <sup>15</sup>INSERM, UMR1153, Paris, France; <sup>16</sup>Centre d'Épidémiologie Clinique, Hôpital Hôtel  
16  
17 Dieu, Assistance Publique–Hôpitaux de Paris, Paris, France; <sup>17</sup>Faculté de Médecine,  
18  
19 Université Paris Descartes, Sorbonne Paris Cité, Paris, France; <sup>18</sup>Health Services  
20  
21 Research Unit, University of Aberdeen, Aberdeen, UK; <sup>19</sup>Department of Cardiology,  
22  
23 Clinical Sciences, Lund University, Lund, Sweden; <sup>20</sup>Department of Psychology, McGill  
24  
25 University, Montréal, Québec, Canada; <sup>21</sup>Scleroderma Society of Ontario, Hamilton,  
26  
27 Canada; <sup>22</sup>Scleroderma Canada, Hamilton, Canada; <sup>23</sup>Health e-Research Centre, School  
28  
29 of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester,  
30  
31 Manchester, UK; <sup>24</sup>Faculty of Science, Division of Pharmacoepidemiology and Clinical  
32  
33 Pharmacology, Utrecht University, Utrecht, the Netherlands; <sup>25</sup>Department of Health  
34  
35 Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada;  
36  
37 <sup>26</sup>Department of Psychiatry, Dalhousie University, Halifax, Canada; <sup>27</sup>University Medical  
38  
39 Center Utrecht, Utrecht, the Netherlands; <sup>28</sup>University of Utrecht, Utrecht, the  
40  
41 Netherlands; <sup>29</sup>NPEU Clinical Trials Unit, National Perinatal Epidemiology Unit,  
42  
43 Nuffield Department of Population Health, University of Oxford, UK; <sup>30</sup>Departments of  
44  
45 Psychiatry; Epidemiology, Biostatistics and Occupational Health; Medicine; and  
46  
47 Educational and Counselling Psychology, McGill University, Montreal, Canada  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 **Address for Correspondence:** Brett D. Thombs, PhD; Jewish General Hospital; 4333  
6  
7 Cote Ste Catherine Road; Montreal, Quebec H3T 1E4; Tel (514) 340-8222 ext. 25112; E-  
8  
9 mail: brett.thombs@mcgill.ca  
10  
11  
12  
13

14  
15 **Author Email Addresses:**

16 kwakkenbosl@gmail.com

17 mahrukh.imran@mail.mcgill.ca

18 kimberlyalba.mccord@usb.ch

19 msampson@cheo.on.ca

20 ole.frobert@regionorebrolan.se

21 christopher.gale@imperial.ac.uk

22 lars.hemkens@usb.ch

23 sinead.langan@lshtm.ac.uk

24 dmoher@ohri.ca

25 c.relton@qmul.ac.uk

26 merrick.zwarenstein@ices.on.ca

27 eric@benchimol.ca

28 isabelle.boutron@aphp.fr

29 m.k.campbell@abdn.ac.uk

30 david.erlinge@gmail.com

31 s.jawad@imperial.ac.uk

32 philippe.ravaud@aphp.fr

1  
2  
3 danielle.rice@mail.mcgill.ca  
4

5 maureen.sauve@gmail.com  
6

7 tjeerd.vanstaa@manchester.ac.uk  
8

9  
10 thabanl@mcmaster.ca  
11

12 uher@dal.ca  
13

14 h.m.verkooijen@umcutrecht.nl  
15

16 ed.juszczak@npeu.ox.ac.uk  
17

18  
19 brett.thombs@mcgill.ca  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Randomized controlled trials (RCTs) conducted using cohorts and routinely collected health data, including registries, electronic health records, and administrative databases, are increasingly used in health care intervention research. The development of an extension of the CONSolidated Standards of Reporting Trials (CONSORT) statement for RCTs using cohorts and routinely collected health data is being undertaken with the goal of improving reporting quality by setting standards early in the process of uptake of these designs. To develop this extension to the CONSORT statement, a scoping review will be conducted to identify potential modifications or clarifications of existing reporting guideline items, as well as additional items needed for reporting RCTs using cohorts and routinely collected health data.

**Methods and analysis:** In separate searches, we will seek publications on methods or reporting or that describe protocols or results from RCTs using cohorts, registries, electronic health records and administrative databases. Data sources will include Medline and the Cochrane Methodology Register. For each of the four main types of RCTs using cohorts and routinely collected health data, separately, two investigators will independently review included publications to extract potential checklist items. A potential item will either modify an existing CONSORT 2010, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) or REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) item or will be proposed as a new item. Additionally, we will identify examples of good reporting in RCTs using cohorts and routinely collected health data.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Ethics and dissemination:** The proposed scoping review will help guide the development of the CONSORT extension statement for RCTs conducted using cohorts and routinely collected health data.

For peer review only

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- Our scoping review will be conducted using rigorous methods, with peer-reviewed searches developed by a research librarian that will comply with Institute of Medicine standards and are not limited by language.
- Due to the novelty of RCTs using cohorts and routinely collected health data, we anticipate identifying only a limited number of methods and reporting articles in our scoping review.
- To supplement articles on methods and reporting, we will review primary trial protocols and reports to identify elements that need reporting and to identify examples of good reporting.

## INTRODUCTION

Randomized controlled trials (RCTs), when well-designed and conducted, are widely acknowledged to be the gold standard for evaluating the effectiveness and harms of medical interventions.<sup>1-3</sup> Important concerns exist, however, about many RCTs, including limitations related to difficulty recruiting sufficiently large and representative samples, limited real-world generalizability, and prohibitive costs.<sup>4-12</sup> To attempt to address these and other challenges, trial designs have been developed in which RCTs are conducted within the frameworks cohorts<sup>4</sup> and routinely collected health data. Routinely collected health data are defined as data collected for administrative and clinical purposes, without specific *a priori* research questions<sup>13</sup>, and include registries<sup>14</sup>, electronic health records<sup>15</sup>, and health administrative databases.<sup>16</sup>

Biomedical research reporting guidelines have been developed to assist authors to report research studies as accurately, transparently, and completely as possible. Reporting guidelines typically describe a minimum set of information that should be clearly reported, provide examples of guideline-consistent reporting, and include a checklist to facilitate compliance.<sup>17,18</sup> Multiple existing reporting guidelines include items that are potentially applicable to RCTs conducted using cohorts and routinely collected health data. In addition to the Consolidated Standards of Reporting Trials (CONSORT) statement for reporting of parallel group RCTs,<sup>19</sup> reporting guidelines with the most direct overlap include the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline for the reporting of observational studies, generally,<sup>20</sup> and the REporting of studies Conducted using Observational Routinely



1  
2  
3 collected Data (RECORD) guideline,<sup>21</sup> which addresses reporting specific to  
4  
5 observational studies conducted using routinely collected health data.  
6

7  
8 The development of an extension of the CONSORT statement for RCTs conducted  
9  
10 using cohorts and routinely collected health data is being undertaken with the goal of  
11  
12 improving long-term reporting quality by setting standards early in the process of uptake  
13  
14 of these trial designs.<sup>22</sup> To develop this CONSORT extension, information is needed to  
15  
16 understand which items from CONSORT, STROBE, and RECORD can be utilized  
17  
18 without modification and which should be included with adaptations, as well as aspects  
19  
20 of reporting of RCTs conducted using cohorts and routinely collected health data that are  
21  
22 not covered adequately in these reporting guidelines and that require new reporting items.  
23  
24 In addition, examples of complete and transparent reporting of different aspects of these  
25  
26 RCTs are needed.  
27  
28  
29

30  
31 Relatively little guidance has been published on the methods and reporting of RCTs  
32  
33 conducted using cohorts and routinely collected health data. To account for this, the  
34  
35 proposed scoping review will identify articles on the methods or reporting of RCTs  
36  
37 conducted using cohorts, registries, electronic health records, and health administrative  
38  
39 databases, as well as examples of protocols and reports of results from these types of  
40  
41 RCTs. The objectives of the scoping review are to (1) determine which items from an  
42  
43 initial long list of items based on CONSORT, STROBE, and RECORD that are being  
44  
45 considered for possible inclusion in the CONSORT extension can be included without  
46  
47 modification, identify items from the initial list that need adaptation, and identify  
48  
49 additional reporting considerations to develop new items; and (2) identify examples of  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 complete and transparent reporting of different aspects of these types of RCTs that can be  
4  
5 used to support the CONSORT extension.  
6

## 7 8 **METHODS** 9

10 The scoping review will be conducted following the approach described by Arksey  
11 and O'Malley<sup>23</sup> and will be reported using the Preferred Reporting Items for Systematic  
12 Reviews and Meta-Analysis: extension for Scoping Reviews (PRISMA-ScR)  
13  
14  
15  
16  
17 guidelines.<sup>24</sup>  
18

### 19 *Database Searches* 20

21 In separate searches, we will seek publications that describe aspects of methods or  
22 reporting or that describe protocols or results from RCTs (including cluster RCTs) using  
23  
24 (1) cohorts; (2) registries; (3) electronic health records; and (4) health administrative  
25  
26 databases. Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed  
27 Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE and EBM Reviews - Cochrane  
28 Methodology Registry (Final issue, 3rd Quarter 2012) will be searched by an experienced  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
librarian familiar with knowledge synthesis for publications on methods or reporting of  
these types of RCTs and for examples of these types of RCTs. MEDLINE strategies for  
the searches were developed by a research librarian with input from the project team and  
were peer reviewed using the Peer Review of the Electronic Search Strategy (PRESS)  
standard.<sup>25</sup> The MEDLINE strategy was then adapted for the Cochrane Library  
Methodology Register, which includes methodological research available up to its last  
update in July 2012.

51 Search strategies comply with Institute of Medicine standards and are not limited  
52  
53  
54  
55  
56  
57  
58  
59  
60  
by language.<sup>26</sup> We will search for articles on methods and reporting and examples of

1  
2  
3 RCTs published in the last 10 years (2008-2018), which will allow us to identify  
4 relatively recent reporting practices and focus on challenging aspects of reporting. See  
5 Supplementary File 1 for detailed search strategies. In addition to the database searches,  
6 references of included studies will be reviewed for additional eligible studies, a web  
7 search will be conducted, and members of the project team with experience in each type  
8 of trial will be consulted to provide additional studies that were not identified in our  
9 search.

### 19 ***Study Selection***

21 For each search, separately, results will be downloaded into the citation  
22 management database RefWorks, and duplicate references will be removed. Following  
23 this, references will be transferred into the systematic review software DistillerSR<sup>®</sup>  
24 (Evidence Partners, Ottawa, Canada). A coding manual based on eligibility criteria has  
25 been developed, and a pilot test of the coding manual will be performed prior to the  
26 study's inception. The initial coding manuals for inclusion and exclusion for all four  
27 types of trial designs are shown in Supplementary File 2. Because the trial designs that  
28 will be included in the CONSORT extension reflect relatively recent developments, we  
29 anticipate that we will identify only a small number of articles on their methodology and  
30 reporting. Thus, we will also include publications of trial protocols and results.

31 We will assess the eligibility of each publication through a two-stage process. In  
32 the first stage, two reviewers will independently screen titles and abstracts to identify  
33 potentially relevant studies. We will use a liberal accelerated method<sup>27</sup> to screen titles and  
34 abstracts, meaning that articles deemed eligible by one of the reviewers will be included  
35 in full-text review, and only excluded articles will be screened by a second reviewer.

1  
2  
3 Since title and abstract screening is done randomly and concurrently, reviewers will not  
4 know if the other reviewer has excluded the reference or not. In the second stage, two  
5 investigators will independently conduct a full-text review. Disagreements after full-text  
6 review will be resolved by consensus, with a third investigator consulted as necessary.  
7  
8 Translators will be consulted to evaluate titles and abstracts and full-text articles for  
9 languages other than those for which team members are fluent, if any. See Supplementary  
10 File 3 for the preliminary PRISMA flow of studies figures for the four types of trial  
11 designs.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 ***Data Extraction and Verification***

23  
24 To develop a preliminary 'long list' of items to consider for the CONSORT  
25 extension checklist, as an initial step, items from the CONSORT 2010 will be examined  
26 to identify items where modifications will be needed for RCTs conducted using cohorts  
27 and routinely collected health data, and items from the STROBE and RECORD reporting  
28 guidelines will be examined to identify additional items to complement CONSORT  
29 items. Two investigators will independently review these reporting guidelines, and any  
30 item deemed possibly relevant to RCTs using cohorts and routinely collected health data  
31 by either or both investigator, will be included in the 'long list'. Additional preliminary  
32 'long list' items will be provided by other members of the project team.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 For each of the four types of RCTs conducted using cohorts and routinely  
45 collected health data, separately, two investigators will independently review included  
46 publications to extract additional potential items for the 'long list'. A potential item will  
47 either modify an existing CONSORT 2010, STROBE or RECORD item that has been  
48 included in the 'long list' or will be proposed as a new item. Potential items will be  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 identified from publications that report information relevant to conducting RCTs using  
4 cohorts and routinely collected health data, but that were not included in our initial ‘long  
5 list’. In addition, potential items will be suggested based on gaps in reporting identified  
6 from primary trial protocols or reports. Data will be extracted and collected in  
7  
8 DistillerSR<sup>®</sup> using a standardized data extraction form. The long-list of items will evolve  
9  
10 dynamically as potential modifications and new items are added based on the review of  
11  
12 publications identified from our literature search using the DistillerSR<sup>®</sup> Dynamic  
13  
14 Question function. Thus, reviewers will add a potential item only once to the long-list,  
15  
16 after which it becomes visible for all reviewers. Reviewers will not duplicate items  
17  
18 already provided by other reviewers. This will be done to avoid redundancy, as we expect  
19  
20 potential gaps in reporting to occur in multiple publications that will be reviewed. In  
21  
22 addition to each proposed item modification or new item, reviewers will add a brief  
23  
24 explanation of why the suggested modification or new item is deemed important.  
25  
26  
27  
28  
29  
30  
31  
32

33 In addition to identifying gaps in reporting, for each item on our long list, we will  
34  
35 attempt to identify examples of complete and transparent reporting in RCTs using  
36  
37 cohorts, registries, electronic health record, and health administrative databases. When  
38  
39 examples of complete and transparent reporting for a particular item on the long list are  
40  
41 identified, text corresponding to reporting of that item will be inserted in the data  
42  
43 extraction form in DistillerSR<sup>®</sup>.  
44  
45  
46

47 Prior to data extraction from included studies, all reviewers will assess a sample  
48  
49 of trial reports. The results will be compared and discussed among the reviewers in order  
50  
51 to ensure consistent application of the data extraction process.  
52  
53

### 54 ***Patient and Public Involvement***

55  
56  
57  
58  
59  
60

1  
2  
3 One of the members of our extension to the CONSORT statement, Maureen  
4 Sauv e, is a patient organization leader. She has been involved in working with  
5 researchers to establish a cohort of patients living with the rare disease scleroderma,  
6 which supports RCTs of trials of online rehabilitation, self-management and  
7 psychological intervention programs<sup>28</sup>.  
8  
9  
10  
11  
12  
13

## 14 **CONCLUSION**

15  
16 This scoping review will gather previously published methods and  
17 recommendations for the reporting of RCTs using cohorts and routinely collected health  
18 data, as well as identify gaps in reporting of these studies. We will identify potential  
19 modifications or clarifications of CONSORT 2010, STROBE and RECORD items as  
20 well as potential additional items to develop an extension to the CONSORT statement for  
21 reporting RCTs using cohorts and routinely collected health data. Following the scoping  
22 review, identified items will be vetted using a 3-stage Delphi approach<sup>29</sup> and a face-to-  
23 face meeting, after which the reporting checklist and explanation and elaboration  
24 documents for the CONSORT extension will be finalized. The resulting CONSORT  
25 extension will promote transparency, clarity, reduce research waste and provide guidance  
26 to researchers on appropriate and consistent reporting of RCTs using cohorts and  
27 routinely collected health data.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **ETHICS AND DISSEMINATION**

45  
46 This study does not require ethics approval, as required data will be collected through the  
47 review of published literature. The proposed scoping review will help guide the  
48 development of the CONSORT extension statement for RCTs conducted using cohorts  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and routinely collected health data. The findings will be disseminated through peer-  
4  
5 reviewed publications and conference presentations.  
6

### 7 **AUTHORS' CONTRIBUTIONS**

8  
9  
10 LK, MI, EJ, LGH, OF, CR, CG, MZ, SML, DM, MS and BDT were involved in initial  
11  
12 phases of study conception, design of the search strategy, and development of conceptual  
13  
14 frameworks. KAM, EIB, IB, MKC, DE, SJ, PR, DR, MS, TPS, LT, RU and H MV  
15  
16 provided regular feedback on each of these steps. LK, MI and BDT were responsible for  
17  
18 the first draft of the manuscript. All authors made substantive intellectual contributions to  
19  
20 the development of this protocol and approved the final version.  
21  
22  
23  
24  
25

### 26 **FUNDING STATEMENT**

27  
28 The development of this CONSORT extension has been funded by grants from  
29  
30 the Canadian Institutes of Health Research (PIs = BDT, OF, EJ, LK, CR; Grant #PJT-  
31  
32 156172), and from the United Kingdom National Institute of Health Research (NIHR)  
33  
34 Clinical Trials Unit Support Funding - Supporting efficient / innovative delivery of NIHR  
35  
36 research (PI EJ, co-applicant CG). Dr. Thombs is supported by a Fonds de recherche du  
37  
38 Québec - Santé researcher salary award. Dr. Gale is supported by the United Kingdom  
39  
40 Medical Research Council through a Clinician Scientist Fellowship. Dr. Langan is  
41  
42 supported by a Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z). Dr.  
43  
44 Uher is supported by the Canada Research Chairs Program (Award #231397). Dr.  
45  
46 Benchimol is supported by a New Investigator Award from the Canadian Institutes of  
47  
48 Health Research, Canadian Association of Gastroenterology and Crohn's and Colitis  
49  
50 Canada, and the Career Enhancement Program of the Canadian Child Health Clinician  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Scientist Program. Ms. Rice is supported by a Vanier CIHR Graduate Scholarship. The  
4  
5 views expressed are those of the authors and not necessarily those of the NHS, the NIHR  
6  
7 or the Department of Health and Social Care.  
8  
9  
10

### 11 12 **COMPETING INTERESTS STATEMENT** 13

14 The authors have read and understood the BMJ policy on declaration of interests and  
15  
16 declare that they have no competing interests.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. Torgerson D, Torgerson C. Designing randomised trials. Basingstoke: Palgrave; 2008.
2. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. *J Chron Dis* 1967;20:637–48.
3. Evans I, Thornton H, Chalmers I, Glasziou P. Testing Treatments: Better research for better healthcare. London: Pinter and Martin Ltd; 2011.
4. Relton C, Torgerson D, O’Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. *BMJ* 2010;340:2.
5. Treweek S, Mitchell E, Pitkethly M, Cook J, Kjeldstrøm M, Taskila T, et al. Strategies to improve recruitment to randomised controlled trials. *Cochrane Database Syst Rev* 2010;4:MRMR000013.
6. Watson J, Torgerson D. Increasing recruitment to randomised trials: a review of randomised controlled trials. *BMC Med Res Methodol* 2006;6:34.
7. Campbell M, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, et al. Recruitment to randomised trials: strategies for trial enrolment and participation study: the STEPS study. *Health Technol Assess* 2007;11:48 iii, ix-105.
8. Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrøm M, Johansen M, et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. *BMJ Open* 2013;3:e002360.

- 1  
2  
3 9. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised,  
4 controlled, multicenter trials: a review of trials funded by two UK funding  
5 agencies. *Trials* 2013;14:166.  
6  
7
- 8  
9  
10 10. McDonald AM, Treweek S, Shakur H, Free C, Knight R, Speed C, et al. Using a  
11 business model approach and marketing techniques for recruitment to clinical trials.  
12 *Trials* 2011;12:74.  
13  
14
- 15 11. Donovan JL, Paramasivan S, De Salis I, Toerien M. Clear obstacles and hidden  
16 challenges: understanding recruiter perspectives in six pragmatic randomised  
17 controlled trials. *Trials* 2014;15:5.  
18  
19
- 20 12. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munis BH, Lindborg SR, et  
21 al. How to improve R&D productivity: the pharmaceutical industry's grand  
22 challenge. *Nat Rev Drug Discov* 2010;9:203-14.  
23  
24
- 25 13. Spasoff RA. *Epidemiologic Methods for Health Policy*. New York: Oxford  
26 University Press, Inc.; 1999.  
27  
28
- 29 14. James S, Fröbert O, Lagerqvist B. Cardiovascular registries: a novel platform for  
30 randomised clinical trials. *Heart* 2012;98:1329-31.  
31  
32
- 33 15. van Staa TP, Dyson L, McCann G, Padmanabhan S, Belatri R, Goldacre B, et al.  
34 The opportunities and challenges of pragmatic point-of-care randomised trials using  
35 routinely collected electronic records: evaluations of two exemplar trials. *Health*  
36 *Technol Assess* 2014;18:1-146.  
37  
38
- 39 16. Anderson GL, Burns CJ, Larsen J, Shaw PA. Use of administrative data to increase  
40 the practicality of clinical trials: Insights from the Women's Health Initiative. *Clin*  
41 *Trials* 2016;13:519-26  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

17. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. *Lancet* 2014;383:267-76.
18. Simera I, Moher D, Hoey J, Schulz K. F., & Altman, D. G. (2010). A catalogue of reporting guidelines for health research. *European journal of clinical investigation*, 40(1), 35-53.
19. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 23;340:c332.
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370:1453-7.
21. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Med.* 2015;12:e1001885.
22. Kwakkenbos L, Juszczak E, Hemkens LG, Sampson M, Fröbert O, Relton C, et al. Protocol for the Development of a CONSORT Extension for Trials Using Cohorts and Routinely Collected Health Data. *Res Integr Peer Rev.* Submitted.
23. Arksey H, O'Malley L. Scoping studies: Towards a Methodological Framework. *International journal of social research methodology.* 2005;8:19-32.
24. Tricco A, Straus S, Moher D. Preferred reporting items for systematic reviews and meta-analysis: extension for Scoping Reviews (PRISMA-ScR). EQUATOR Netw

- 1  
2  
3 [http://www.equator-network.org/wp-content/uploads/2009/02/Executive-](http://www.equator-network.org/wp-content/uploads/2009/02/Executive-summary_ScR_Dec-9.pdf)  
4 [summary\\_ScR\\_Dec-9.pdf](http://www.equator-network.org/wp-content/uploads/2009/02/Executive-summary_ScR_Dec-9.pdf) (accessed 20 May 2017). 2017.  
5  
6  
7  
8 25. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS  
9 peer review of electronic search strategies: 2015 guideline statement. *J Clin*  
10 *Epidemiology* 2016;75:40-6.  
11  
12  
13  
14 26. Institute of Medicine. (2011). Finding What Works in Health Care: Standards for  
15 Systematic Reviews. Standard 3.1 Conduct a comprehensive systematic search for  
16 evidence. Washington DC: Institute of Medicine. Available  
17 at [http://iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-](http://iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews/Standards.aspx)  
18 [Systematic-Reviews/Standards.aspx](http://iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews/Standards.aspx). Accessed 13 March 2018.  
19  
20  
21  
22  
23  
24  
25  
26 27. Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence summaries:  
27 the evolution of a rapid review approach. *Syst Rev* 2012;1:10.  
28  
29  
30  
31 28. Kwakkenbos L, Jewett LR, Baron M, Bartlett SJ, Furst D, Gottesman K, et al. The  
32 Scleroderma Patient-centered Intervention Network (SPIN) Cohort: Protocol for a  
33 cohort multiple randomized controlled trial (cmRCT) design to support trials of  
34 psychosocial and rehabilitation interventions in a rare disease context. *BMJ Open*  
35 2013;3:e003563.  
36  
37  
38  
39  
40  
41  
42 29. Trevelyan E, Robinson N. Delphi methodology in health research: how to do it?  
43 *Eur J of Int Med* 2015;7:423-428.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Supplementary File 1 – Electronic Search Strategies

Searches were run in both MEDLINE and Cochrane Methodology Register simultaneously. As an example, in the registries search, lines 1-11 are the MEDLINE search and lines 12-15 are tailored for the Cochrane Methodology Register. The final lines of each search isolate the records from each database, combine them so duplicate records can be removed, then isolate the remaining records so they can be downloaded and imported into Reference Manager using customized import filters.

### Searches for RCTs embedded in Registries

1. ((registry or registries) adj5 randomi#ed).ab,kf,ti.
2. ((registry or registries) adj5 RCT\*).ab,kf,ti.)
3. ((registry or registries) adj5 controlled trial\*).ab,kf,ti.
4. ((registry or registries) adj5 (RRCT\* or R RCT\*)).ab,kf,ti.
5. or/1-4
6. (meta analy\* or metaanaly\* or metanaly\* or systematic review\*).af.
7. 5 not 6
8. Registries/
9. limit 8 to randomized controlled trial
10. 7 or 9
11. limit 10 to yr="2007 - 2018"
12. (registry or registries).ab,kf,ti.
13. (random\* or RCT).ti,ab,kw.
14. 12 and 13
15. limit 14 to yr="2007 - 2018"
16. 11 use medall
17. 15 use clcmr
18. 16 or 17 (1240)
19. remove duplicates from 18
20. 19 use medall
21. 19 use clcmr

### Searches for RCTs embedded in Cohorts

1. (cohort adj5 (randomi#ed adj5 trial\*)).ab,kf,ti.
2. (cohort adj5 RCT\*).ab,kf,ti.
3. (cohort adj5 controlled trial\*).ab,kf,ti.
4. (cmRCT or Cohort Multiple Randomised Controlled Trial\*).ab,kf,ti.
5. or/1-4
6. cohort.af.
7. (embed\* adj8 randomi#ed).ab,kf,ti.
8. (embed\* adj8 RCT\*).ab,kf,ti.
9. (embed\* adj8 controlled trial\*).ab,kf,ti.
10. or/7-9
11. 6 and 10
12. (pragmatic adj5 RCT\*).ab,kf,ti.
13. (pragmatic adj5 randomi#ed).ab,kf,ti.

14. (pragmatic adj5 controlled trial\*).ab,kf,ti.
15. or/12-14
16. 6 and 15
17. 5 or 11 or 16
18. (meta analy\* or metaanaly\* or metanaly\* or systematic review\*).af.
19. 17 not 18
20. limit 19 to yr="2007 - 2018"
21. ((Cohort\* and (random\* or RCT)) or cmRCT).ti,ab,kw.
22. limit 21 to yr="2007 - 2018"
23. 20 use medall
24. 22 use clcmr
25. 23 or 24
26. remove duplicates from 25
27. 26 use medall
28. 26 use clcmr

### Searches for RCTs embedded in Electronic Health Records

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomi?ed.ab.
4. placebo.ab.
5. randomly.ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Electronic Health Records/
12. (EHR or electronic health record\*).ab,kf,ti.
13. (EMR or electronic medical record\*).ab,kf,ti.
14. (PHR or personal health record\*).ab,kf,ti.
15. (EPR or electronic patient record\*).ab,kf,ti.
16. exp Health Records, Personal/
17. or/11-16
18. 10 and 17
19. limit 18 to yr="2007 - 2018"
20. (Electronic health record or electronic health records or EHR).ti,ab,kw.
21. (Electronic medical record or electronic medical records or EMR).ti,ab,kw.
22. (Electronic patient record or electronic patient records or EPR).ti,ab,kw.
23. or/20-22
24. limit 23 to yr="2007 - 2018"
25. 19 use medall
26. 24 use clcmr
27. 25 or 26
28. remove duplicates from 27
29. 28 use medall
30. 28 use clcmr

### Searches for RCTs embedded in Administrative Databases

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomi?ed.ab.
4. placebo.ab.
5. randomly.ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. administrative data\*.ab,kf,ti.
12. healthcare data\*.ab,kf,ti.
13. health care data\*.ab,kf,ti.
14. or/11-13
15. 10 and 14
16. (administrative adj5 data\*).ti,ab,kw.
17. health care data\*.ti,ab,kw.
18. healthcare data\*.ti,ab,kw.
19. or/16-18
20. (random\* or RCT).ti,ab,kw.
21. 19 and 20
22. limit 15 to yr="2007 - 2018"
23. 22 use medall
24. limit 21 to yr="2007 - 2018"
25. 22 use clcmr

## Supplementary File 2 – Coding Manual

### Title/Abstract Screening

#### **Does this study meet the title and abstract inclusion criteria for Cohort-based Randomized Controlled Trials (RCTs)?**

**No: not an RCT using a cohort.** If it is clear from the title and abstract that the publication does not describe (1) issues related to methods or reporting of cohort-based RCTs, (2) a cohort intended to be used to conduct RCTs, or (3) a protocol or results from a RCT that will select or selected individuals from a cohort, it is excluded. For the purpose of this review, a cohort is defined as a group of individuals who are gathered for the purpose of conducting research and for whom there are multiple assessments over time. If it is clear from the title and abstract that the publication describes a study that enrolls patients only in a cohort or only in an RCT (e.g., comparative cohort trials, parallel cohorts) – but not both, it is excluded. If (observational) analyses are done on all participants or a subgroup of participants who were enrolled in an RCT, even if described by the authors as a 'cohort', it would be excluded. If the RCT involves non-human subjects, it is excluded.

**No: the cohort is only used for identifying eligible participants.** If it is clear from the title and abstract that the publication describes a trial in which a cohort was solely used to identify eligible trial participants, but for no other purposes related to the trial, it is excluded.

**No: the cohort is only used for collecting trial outcomes.** If it is clear from the title and abstract that the publication describes a trial that only links to a cohort to ascertain health outcomes as trial endpoints, but does not otherwise use the cohort in the trial, it is excluded.

**Yes: study eligible to be included in full-text review.**



1  
2  
3 **Does this study meet the title and abstract inclusion criteria for Registry-based**  
4 **Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using a registry.** If it is clear from the title and abstract that the  
8 publication does not describe (1) issues related to methods or reporting of registry-based  
9 RCTs, (2) a registry used to conduct RCTs, or (3) a protocol or results from a RCT  
10 conducted using a registry, it is excluded. A registry has been defined by the European  
11 Medicines Agency as “an organized system that uses observational methods to collect  
12 uniform data on specified outcomes in a population defined by a particular disease,  
13 condition, or exposure, and that is followed over time.” Entry in a registry is generally  
14 defined either by diagnosis of a disease (disease registry) or prescription of a drug,  
15 device, or other treatment (exposure registry). If the RCT involves non-human subjects, it  
16 is excluded.  
17  
18

19 **No: the registry is only used for identifying eligible participants.** If it is clear from the  
20 title and abstract that the publication describes a trial in which the registry was solely  
21 used to identify eligible trial participants, but for no other purposes related to the trial, it  
22 is excluded.  
23  
24

25 **No: the registry is only used for collecting trial outcomes.** If it is clear from the title  
26 and abstract that the publication describes a trial that only links to a registry to ascertain  
27 health outcomes as trial endpoints, but does not otherwise use the registry in the trial, it is  
28 excluded.  
29  
30

31 **Yes: study eligible to be included in full-text review.**  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Does this study meet the title and abstract inclusion criteria for Administrative**  
4 **Database-based Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using administrative data.** If it is clear from the title and abstract that  
8 the publication does not describe (1) issues related to methods or reporting of  
9 administrative database-based RCTs, (2) an administrative dataset used to conduct RCTs,  
10 or (3) a protocol or results from a RCT conducted using an administrative database, it is  
11 excluded. Administrative data refers to information collected primarily for administrative  
12 purposes (e.g., all users of healthcare in a province, all persons enrolled in a health  
13 insurance plan). If the RCT involves non-human subjects, it is excluded.  
14

15  
16 **No: the administrative database is only used for identifying eligible participants.** If it  
17 is clear from the title and abstract that the publication describes a trial in which the  
18 administrative database was solely used to identify eligible trial participants, but for no  
19 other purposes related to the trial, it is excluded.  
20

21  
22 **No: the administrative database is only used for collecting trial outcomes.** If it is  
23 clear from the title and abstract that the publication describes a trial that only links to an  
24 administrative database to ascertain health outcomes, as trial endpoints, but does not  
25 otherwise use the administrative database in the trial, it is excluded.  
26

27 **Yes: study eligible to be included in full-text review.**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Does this study meet the title and abstract inclusion criteria for Electronic Health**  
4 **Record (EHR)-based Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using EHRs.** If it is clear from the title and abstract that the publication  
8 does not describe (1) issues related to methods or reporting of electronic health records  
9 (EHR)-based RCTs, (2) EHRs that will be used to conduct RCTs, or (3) a protocol or  
10 results from a RCT conducted using EHRs, it is excluded. EHRs are electronic versions  
11 of a patient's medical history, and can include information that includes diagnoses,  
12 medications, and treatment plans, for instance. If the RCT involves non-human subjects,  
13 it is excluded.  
14

15  
16 **No: the EHR is only used for identifying eligible participants.** If it is clear from the  
17 title and abstract that the publication describes a trial in which the EHR was solely used  
18 to identify eligible trial participants, but for no other purposes related to the trial, it is  
19 excluded.  
20

21  
22 **No: the EHRs is only used to ascertain health outcomes.** If it is clear from the title and  
23 abstract that the publication describes a trial that only links to EHRs to ascertain health  
24 outcomes, as trial endpoints, but does not otherwise use EHRs in the trial, it will be  
25 excluded.  
26

27 **Yes: study eligible to be included in full-text review.**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Full-text review

### Does this study meet the inclusion criteria for Cohort-based Randomized Controlled Trials (RCTs)?

**No: not an RCT using a cohort.** If the publication does not describe (1) issues related to methods or reporting of cohort-based RCTs, (2) a cohort intended to be used to conduct RCTs, or (3) a protocol or results from a RCT that will select or selected individuals from a cohort, it is excluded. For the purpose of this review, a cohort is defined as a group of individuals who are gathered for the purpose of conducting research and for whom there are multiple assessments over time. If it is clear from the title and abstract that the publication describes a study that enrolls patients only in a cohort or only in an RCT (e.g., comparative cohort trials, parallel cohorts) – but not both, it is excluded. If (observational) analyses are done on all participants or a subgroup of participants who were enrolled in an RCT, even if described by the authors as a 'cohort', it would be excluded. If the RCT involves non-human subjects, it is excluded.

**No: the cohort is only used for identifying eligible participants.** If the publication describes a trial in which a cohort was solely used to identify eligible trial participants, but for no other purposes related to the trial, it is excluded.

**No: the cohort is only used for collecting trial outcomes.** If the publication describes a trial that only links to a cohort to ascertain health outcomes as trial endpoints, but does not otherwise use the cohort in the trial, it is excluded.

**Yes: study eligible to be included in scoping review.**

1  
2  
3 **Does this study meet the inclusion criteria for Registry-based Randomized**  
4 **Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using a registry.** If the publication does not describe (1) issues related  
8 to methods or reporting of registry-based RCTs, (2) a registry used to conduct RCTs, or  
9 (3) a protocol or results from a RCT conducted using a registry, it is excluded. A registry  
10 has been defined by the European Medicines Agency as “an organized system that uses  
11 observational methods to collect uniform data on specified outcomes in a population  
12 defined by a particular disease, condition, or exposure, and that is followed over time.”  
13 Entry in a registry is generally defined either by diagnosis of a disease (disease registry)  
14 or prescription of a drug, device, or other treatment (exposure registry). If the RCT  
15 involves non-human subjects, it is excluded.  
16

17  
18 **No: the registry is only used for identifying eligible participants.** If the publication  
19 describes a trial in which the registry was solely used to identify eligible trial participants,  
20 but for no other purposes related to the trial, it is excluded.  
21

22  
23 **No: the registry is only used for collecting trial outcomes.** If the publication describes  
24 a trial that only links to a registry to ascertain health outcomes as trial endpoints, but does  
25 not otherwise use the registry in the trial, it is excluded.  
26

27 **Yes: study eligible to be included in scoping review.**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Does this study meet the inclusion criteria for Administrative Database-based**  
4 **Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using administrative data.** If it the publication does not describe (1)  
8 issues related to methods or reporting of administrative database-based RCTs, (2) an  
9 administrative dataset used to conduct RCTs, or (3) a protocol or results from a RCT  
10 conducted using an administrative database, it is excluded. Administrative data refers to  
11 information collected primarily for administrative purposes (e.g., all users of healthcare  
12 in a province, all persons enrolled in a health insurance plan). If the RCT involves non-  
13 human subjects, it is excluded.  
14

15  
16 **No: the administrative database is only used for identifying eligible participants.** If  
17 the publication describes a trial in which the administrative database was solely used to  
18 identify eligible trial participants, but for no other purposes related to the trial, it is  
19 excluded.  
20

21  
22 **No: the administrative database is only used for collecting trial outcomes.** If the  
23 publication describes a trial that only links to an administrative database to ascertain  
24 health outcomes, as trial endpoints, but does not otherwise use the administrative  
25 database in the trial, it is excluded.  
26

27 **Yes: study eligible to be included in scoping review.**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Does this study meet the inclusion criteria for Electronic Health Record (EHR)-**  
4 **based Randomized Controlled Trials (RCTs)**  
5

6  
7 **No: not an RCT using EHRs.** If the publication does not describe (1) issues related to  
8 methods or reporting of electronic health records (EHR)-based RCTs, (2) EHRs that will  
9 be used to conduct RCTs, or (3) a protocol or results from a RCT conducted using EHRs,  
10 it is excluded. EHRs are electronic versions of a patient's medical history, and can  
11 include information that includes diagnoses, medications, and treatment plans, for  
12 instance. If the RCT involves non-human subjects, it is excluded.  
13


14  
15 **No: the EHR is only used for identifying eligible participants.** If the publication  
16 describes a trial in which the EHR was solely used to identify eligible trial participants,  
17 but for no other purposes related to the trial, it is excluded.  
18

19  
20 **No: the EHRs is only used to ascertain health outcomes.** If the publication describes a  
21 trial that only links to EHRs to ascertain health outcomes, as trial endpoints, but does not  
22 otherwise use EHRs in the trial, it will be excluded.  
23

24 **Yes: study eligible to be included in scoping review.**  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


## Supplementary File 3

## Draft Flow Diagram of Study Selection Process - Cohorts






## Draft Flow Diagram of Study Selection Process - Registries



### Draft Flow Diagram of Study Selection Process – Administrative data



### Draft Flow Diagram of Study Selection Process – Electronic Health Records (EHRs)

